BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.18.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20260101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270326
DTSTAMP:20261112T125518Z
CREATED:20261112T125300Z
LAST-MODIFIED:20261112T125518Z
UID:44759-1805760000-1806019199@www.pharmajournalist.com
SUMMARY:10th Antigen-Specific Immune Tolerance Summit
DESCRIPTION:The 10th Antigen-Specific Immune Tolerance Summit returns to Boston this March\, bringing together the scientific\, clinical\, and industry leaders advancing antigen-specific therapies for autoimmune disease. \nAs leading programs generate pivotal clinical data and progress toward key development milestones\, the field is entering a new phase of clinical and commercial maturity. The meeting is designed to address the challenges most critical to developers of antigen-specific therapies\, including defining durable tolerance\, identifying meaningful biomarkers\, improving translational success\, optimizing antigen selection\, and generating the evidence needed to support regulatory and investment decisions. \nThe speaker faculty includes leaders from Diamyd Medical\, COUR Pharmaceuticals\, Parvus Therapeutics\, Eli Lilly & Co.\, Pfizer\, Bonsai Biotherapeutics\, and Boehringer Ingelheim\, alongside experts from academia\, investment\, and nonprofit organizations. Attendees will gain practical insights from both preclinical and clinical experience across autoimmune indications\, with discussions spanning development strategy\, biomarker selection\, trial design\, and commercialization pathways. \nView the full program to see what insights you can gain: https://ter.li/5tilo5ny \nKey sessions will explore clinically relevant biomarkers of tolerance\, the predictive value of preclinical models\, monitoring technologies for assessing therapeutic efficacy\, and the growing interest in combination approaches to achieve durable immune tolerance. Dedicated discussions on partnership and investment will also examine the evidence pharmaceutical companies and investors seek when evaluating emerging immune tolerance platforms. \nFor the first time\, the summit will take place as part of World Immune Tolerance Week\, alongside the 9th Treg-Directed Therapies Summit and the 2nd Immune Resetting: B-Cell Mediated & Beyond Summit. This co-located format provides broader visibility into complementary therapeutic approaches and opportunities to connect with decision-makers from across immunology\, autoimmune disease\, and precision medicine. \nSee what the previous attendees have to say: \n“It is truly the annual meeting in the ASIT field\, bringing together a community dedicated to sharing knowledge\, exchanging insights\, and celebrating the advances shaping the field”. \nChief Executive Officer\, Bonsai Biotherapeutics \n“As antigen-specific tolerance rapidly transitions from concept to clinic\, this summit stands out as a unique forum bridging immunology\, bioengineering\, and therapeutic development”. \nInstructor\, Division of Immunology & Rheumatology\, Stanford University \nCo-Founder & Scientific Advisor\, EBVio
URL:http://www.pharmajournalist.com/event/10th-antigen-specific-immune-tolerance-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR